Cockayne syndrome: a guide for families

Cockayne syndrome is a rare inherited disorder in which cells cannot repair a specific type of damage to their DNA. Children with the condition grow very slowly, their heads remain small, and the nervous system deteriorates progressively; hearing, vision, teeth and the skin’s tolerance of sunlight are also affected. The overall picture resembles premature ageing. It is caused by mutations in one of two genes, ERCC6 (type B) or ERCC8 (type A), and is inherited from both parents. There is no cure today, and care is supportive.¹²

This guide is written by the Viljem Julijan Association for Children with Rare Diseases, which funds research into gene therapy for Cockayne syndrome type B. It is based on published medical literature, listed in full at the end of the page.

What is Cockayne syndrome?

Cockayne syndrome (CS) is a multisystem genetic disorder, first described by the British paediatrician Edward Cockayne in 1936. Its defining features are a failure to grow after birth, a head that becomes progressively small for the child’s age (microcephaly), developmental delay followed by neurological deterioration, sensitivity of the skin to sunlight, and loss of hearing and vision.¹¹⁰

The underlying problem is in transcription-coupled nucleotide excision repair (TC-NER), a repair system that removes damage blocking the reading of active genes — for example the damage ultraviolet light causes. When the repair proteins CSB (made by ERCC6) or CSA (made by ERCC8) do not work, damaged DNA blocks transcription and cells cannot recover normally.¹

Failure of this one repair pathway explains the sun sensitivity, but it is unlikely to explain the growth failure and the progressive brain disease. Research suggests that CSB and CSA proteins also have roles in restarting transcription after stress, in repairing oxidative damage, and in mitochondrial function — and that Cockayne syndrome arises from the interplay of DNA damage, transcriptional dysregulation and mitochondrial dysfunction.¹¹²²⁰

It is important to understand that Cockayne syndrome is a continuous spectrum rather than a set of separate diseases. GeneReviews states explicitly that the subtype labels used below are somewhat arbitrary and that intermediate forms occur.¹

How common is Cockayne syndrome?

Cockayne syndrome is very rare. The most-cited European study, which pooled the diagnostic DNA repair laboratories of France, Germany, Italy, the Netherlands and the United Kingdom, found a minimum incidence of 2.7 per million live births in western Europe.⁶ MedlinePlus gives a similar estimate of about 2 to 3 per million newborns in the United States and Europe.² A nationwide survey in Japan estimated 2.77 per million births, with a point prevalence of roughly one in 2.5 million people.⁷ Orphanet, the European reference database for rare diseases, records a birth prevalence in Europe of about 0.2 per 100,000 — again around two children per million.⁴

These numbers are probably underestimates, because the diagnosis depends heavily on recognising sun sensitivity, which is mild or absent in a substantial minority of patients.¹⁰ Boys and girls are affected equally, and the condition has been reported in many different populations.⁵

A note on a figure you may see online: the often-quoted “1.8 per million” is from the same European study, but it refers to Cockayne syndrome in the native western European population only, not to a particular genetic type.⁶

Types of Cockayne syndrome

Doctors describe the condition in two different ways, and the two systems are easy to confuse.

By severity — types I, II and III, plus the prenatal form COFS:

Sources: GeneReviews spectrum table and the severity-group study of Natale.¹⁸

By gene — type A and type B (see below). A child can therefore have, for example, Cockayne syndrome type B (the gene) presenting as the classic type I form (the severity).

COFS syndrome (cerebro-oculo-facio-skeletal syndrome, historically Pena–Shokeir syndrome type II) is now regarded as the most severe, prenatal end of the same spectrum. It can be suspected on prenatal ultrasound because of joint contractures (arthrogryposis), poor growth, a small head and congenital cataracts or small eyes.¹

A fourth group has been described in adults whose only manifestation is ultraviolet sensitivity, with late onset of other features.⁸

What causes Cockayne syndrome?

Cockayne syndrome is caused by mutations (pathogenic variants) in one of two genes:

• ERCC6 on chromosome 10q11.23, which makes the CSB protein — about 65–70% of all cases. This is Cockayne syndrome type B.
• ERCC8 on chromosome 5q12.1, which makes the CSA protein — about 30–35% of cases. This is Cockayne syndrome type A.¹⁵¹⁰

Dozens of different disease-causing variants have been described in each gene; many ERCC6 variants shorten the CSB protein, while others change a single building block.³ The mechanism of disease is loss of function: the protein is missing or does not work.¹

There is no clear overall genotype–phenotype correlation, although ERCC8 variants have been associated with somewhat less severe findings at diagnosis than ERCC6 variants.¹

How it is inherited

Cockayne syndrome is autosomal recessive. Both parents carry one faulty copy of the gene and are themselves healthy — carriers have no symptoms and are not at risk. In each pregnancy of two carriers there is a:

• 25% chance the child is affected,
• 50% chance the child is a healthy carrier,
• 25% chance the child inherits neither faulty copy.¹

Once the family’s exact variants are known, carrier testing for relatives, prenatal testing and preimplantation genetic testing all become possible. Families are strongly advised to see a clinical geneticist or genetic counsellor.¹

Cockayne syndrome type B (CSB)

Cockayne syndrome type B is the form caused by mutations in ERCC6, and it is the more common of the two genetic groups: roughly two in three children with Cockayne syndrome have type B.¹¹⁰ In the largest natural history study, 28 of 40 genetically confirmed families (70%) had ERCC6/CSB variants.¹⁰

The CSB protein is large — 1,493 amino acids — and does much more than repair: it helps RNA polymerase II move past lesions, participates in the repair of oxidative damage, and influences mitochondrial function. Its size matters greatly for treatment development, as explained in the research section below.²⁰

Symptoms in type B are the same spectrum as in type A, and severity varies from the prenatal COFS form to mild, late-onset disease. In the natural history cohort, having a CSB rather than a CSA variant was associated with somewhat shorter survival, though the association was only borderline statistically significant.¹⁰

The mission of our association is to help develop a gene therapy for exactly this form of the condition — see Cure for children with Cockayne syndrome type B and our research page.

Symptoms of Cockayne syndrome

Symptoms vary in severity and appear at different ages, but the pattern is consistent. Percentages below come from the Cockayne Syndrome Natural History study of 102 individuals (CoSyNH) and from GeneReviews.¹¹⁰

Growth and appearance

• Failure to grow after birth: height and weight below the 5th centile by age 2 in the classic form; from birth in the severe form. Disease-specific growth charts exist.¹⁶
• Progressive microcephaly — a head that grows too slowly.
• A characteristic thin appearance with sunken eyes (“cachectic dwarfism”), a beaked nose and prominent ears.
• Loss of subcutaneous fat (56%).

Brain and nerves

• Early developmental delay, followed by progressive loss of skills in all affected individuals.
• Brain imaging is abnormal in 83.5%: dysmyelination of white matter, cerebral and cerebellar atrophy, and calcium deposits (55%), often in the basal ganglia.
• Tremor (66%), unsteady gait and ataxia, increased muscle tone or spasticity, weakness (79%), seizures (23%).
• A demyelinating peripheral neuropathy, detectable on nerve conduction studies.
• In the small group who reach adulthood, almost all have neurocognitive or neuropsychiatric decline.¹³

Eyes

• Pigmentary retinopathy — reported in 60–100% of the classic form; a “salt and pepper” retina.
• Cataracts — reported in 15–36% of the classic form and in 48.5% of the natural history cohort, of which 86% appeared by age 4; congenital cataracts or other structural eye anomalies occur in about 30% of the severe form. Cataracts before age 3 are an important prognostic sign.¹¹⁰
• Photophobia, reduced or absent tears, optic atrophy, strabismus, nystagmus.

Hearing

• Progressive hearing loss in all forms, almost always in both ears — present in the newborn period in about 21% of children and in 84% by age 10. It is usually sensorineural (nerve-type), but among the children who had detailed testing in the natural history study, 44% also had a conductive or mixed component — worth asking about, because some of that can be treated. Hearing aids are widely used and cochlear implants have been successful in some children.

Teeth and skin

• Dental caries (46%), enamel defects, missing or abnormally shaped teeth, delayed eruption, malocclusion.
• Sun sensitivity: variable. Almost a quarter of individuals in CoSyNH (23 of 99) had no sun sensitivity at all, which is why the diagnosis is often missed.
• Thin, dry hair (46%); skin pigmentation changes.

The rest of the body

• Cold hands and feet — the most common non-cardinal feature (88%) — and difficult venous access (70%).
• Feeding difficulties (48%) and reflux (57%); many children eventually need a gastrostomy tube.
• Abnormal liver blood tests (63% of those tested), usually mildly raised transaminases.
• High blood pressure (18%), kidney problems including proteinuria, and in the Japanese series severe renal failure in the terminal stages of some patients.⁷
• Joint contractures (64%) and scoliosis (48%).
• Recurrent chest infections, usually caused by food or drink going the wrong way. If your child keeps getting chest infections, ask for a swallowing assessment rather than only another course of antibiotics — a speech and language therapist is a core part of the team here, both for eating and for communication.¹⁰²⁵
• Hormones: some children develop an underactive thyroid or problems with blood sugar — about one in eight of those tested in the natural history study — and puberty is often late or absent. This is why the yearly blood tests include glucose.¹⁰¹

The natural history study found that immune problems are not a feature of Cockayne syndrome, and that children with it do not get more infections than other children apart from those caused by food or drink going the wrong way.¹⁰ A 2026 review has questioned how settled that is, noting that serious infections have been described in severely affected children and that nobody has yet studied their immune systems properly.²⁴ If your child has repeated serious infections, it is reasonable to ask for that to be looked into rather than assumed.

How is Cockayne syndrome diagnosed?

Clinical suspicion. Current practice uses two major criteria and a set of minor criteria.¹

• Major criteria (both needed): growth failure with height and weight below the 5th centile by age 2; progressive microcephaly with neurological dysfunction, with an MRI showing white-matter dysmyelination and cerebral/cerebellar atrophy.
• Minor criteria: sun sensitivity; demyelinating peripheral neuropathy; pigmentary retinopathy and/or cataracts; sensorineural hearing loss; dental anomalies; the typical “cachectic” appearance with sunken eyes.

Because sun sensitivity is so variable, the CoSyNH team proposed a practical alert: consider Cockayne syndrome in any child with growth failure and microcephaly plus any two of persistently cold hands and feet, bilateral hearing loss, sun sensitivity, tremor, joint contractures, progressive loss of body fat, cataracts, or the typical facial appearance. Using this alert would have identified about 90% of their cohort, compared with 36% using older criteria.¹⁰

Genetic testing confirms the diagnosis: two pathogenic variants in ERCC6 or ERCC8, found by a multigene panel or by exome or genome sequencing. Testing can usually be done from a blood, mouthwash or dried blood spot sample, so a skin biopsy is not always needed. A confirmed genetic diagnosis also gives the family a precise recurrence risk and makes prenatal testing possible.¹¹⁰

Cellular testing is the second line when the clinical picture fits but genetic testing is inconclusive. Skin fibroblasts are exposed to ultraviolet light; cells from people with Cockayne syndrome are unusually sensitive and show deficient recovery of RNA synthesis afterwards, while ordinary (global-genome) repair remains normal — a pattern that distinguishes Cockayne syndrome from xeroderma pigmentosum.¹¹⁴

After diagnosis, GeneReviews recommends a baseline set of assessments: growth and feeding, development, brain MRI and neurological examination, eyes, hearing, skin, teeth, skeletal X-rays if indicated, kidney and liver blood tests, blood pressure, genetic counselling, and family support.¹

Life expectancy and prognosis

Cockayne syndrome shortens life, but the range is wide and depends on severity.

These are the figures from the severity-group analysis by Natale.⁸ GeneReviews gives a mean age at death of 16 years for the classic form, with survival into the third decade reported, death usually by age 5 in the severe form, and long-term survival into adulthood in the mild form.¹ A 2024 study identified 18 individuals in the United States, France and the United Kingdom who lived beyond 18 years.¹³

The widely repeated figure of “an average lifespan of 12 years” comes from a review of 140 published cases in 1992 and is still quoted in recent reviews.⁹¹² The severity-specific numbers above are more informative for an individual family.

What predicts a more severe course? The single most useful prognostic sign is cataracts before the age of 3: in the natural history study, five-year survival was about 60% for children with early cataracts, compared with about 95% for those without. Early cataracts were also associated with earlier hearing loss and contractures. The degree of sun sensitivity, by contrast, did not predict survival.¹⁰⁹

Treatment and management

Please read this section with your child's own team. What follows is what the published literature describes, not medical advice, and it cannot take account of your own child. The medicines named below are examples of what specialist teams commonly use — not recommendations for any particular child.

There is no cure and no treatment that changes the course of the disease. No professional body has issued a formal clinical practice guideline,¹ but the natural history study published practical care recommendations that specialist teams follow, and care is best delivered by a multidisciplinary team with one named clinician coordinating it.¹⁰

Commonly used measures:¹

• Nutrition: feeding support, and a gastrostomy when oral feeding is no longer enough; increases in feed volume should be gradual.
• Development: early intervention, physiotherapy, occupational therapy and speech-language therapy.
• Movement: physiotherapy to limit contractures; baclofen for spasticity; carbidopa–levodopa may be considered for tremor.
• Eyes: standard treatment of cataracts; sunglasses to protect lens and retina.
• Hearing: hearing aids, and cochlear implants where appropriate.
• Teeth: aggressive preventive dental care.
• Skin: sunscreen, clothing and limiting sun exposure.
• Other: proton pump inhibitor for reflux; amlodipine or an ACE inhibitor for high blood pressure.

Recommended surveillance: growth and nutrition every six months; eye assessment every six months until age 4, then yearly; hearing yearly; and annual checks of blood pressure, blood glucose, liver enzymes and kidney function including uric acid and protein in the urine.¹ Experienced teams also check blood pressure at every hospital admission and ask that venous access be attempted only by experienced staff.¹⁰

Medicines and exposures to avoid

• Metronidazole must be avoided in any circumstance. It has caused acute liver failure in children with Cockayne syndrome, with a presentation resembling untreated paracetamol overdose, and deaths have occurred. Related antibiotics should be avoided or used with extreme caution and close monitoring of liver function.¹¹¹¹⁰
• Opioids and sedatives may produce exaggerated or prolonged responses.¹¹⁰
• Growth hormone is not recommended: there are no safety or efficacy data in Cockayne syndrome.¹
• Excessive sun exposure should be avoided even when a child does not burn easily.¹
• Anaesthesia needs planning. Facial features, a small mouth, a short neck and possible narrowing below the vocal cords can make ventilation and intubation difficult; anaesthetists are advised to use a videolaryngoscope as their first choice and to have smaller breathing tubes ready. Reflux increases the risk of stomach contents entering the lungs, and contractures make putting in a drip harder. Nutrition, blood pressure and kidney function should be checked before surgery; low blood pressure should be treated promptly, because these children are vulnerable to heart and stroke events, and monitoring should continue after the operation.²¹

There is no evidence of general toxicity from other medicines metabolised by the liver.¹⁰

This is the one thing worth telling every doctor your child ever sees — including out of hours, in the emergency department and at the dentist. In the case series behind the warning, eight children with Cockayne syndrome developed sudden liver failure after metronidazole and three of them died, six to eleven days after the first dose; the authors could not find a single child with Cockayne syndrome who had taken it without a serious reaction, and they recommend treating the diagnosis as an absolute contraindication.¹¹ Many families carry a written alert card or a letter from their specialist. Share & Care publishes emergency-room guidance you can print and keep in the bag.

Does Cockayne syndrome cause cancer?

No. Although the cells cannot repair ultraviolet damage and the skin may be very sun sensitive, people with Cockayne syndrome are not predisposed to skin cancer, and there is no evidence of an increased risk of cancer in general. GeneReviews lists skin-cancer predisposition as “none” for every form of the condition, and the natural history study reached the same conclusion; in the 1992 review of 140 cases, cancer had never been reported in a classic patient.¹¹⁰⁹

One proposed explanation is that transcription and cell proliferation are impaired at the same time.¹ In fact, cancer of any kind in a child under investigation for Cockayne syndrome argues against the diagnosis and should prompt doctors to look for something else.¹

The exception is the combined xeroderma pigmentosum–Cockayne syndrome (XP-CS) complex, which does carry a skin-cancer risk.¹⁵

Conditions that look similar

• Xeroderma pigmentosum (XP): also a DNA repair disorder with sun sensitivity, but most people with XP grow and develop normally — about a quarter do develop progressive neurological problems — and they have an extreme risk of skin cancer — over 10,000-fold for non-melanoma skin cancer under the age of 20 — which people with Cockayne syndrome do not.¹⁴
• XP-CS complex: freckling and early skin cancers typical of XP combined with features of Cockayne syndrome; caused by variants in ERCC2, ERCC3, ERCC4 or ERCC5.¹⁴¹⁵
• COFS syndrome: the prenatal end of the Cockayne spectrum.¹
• UV-sensitive syndrome: the same cellular transcription defect, sometimes the same genes, but only mild sun sensitivity, without growth failure or brain involvement.¹
• Other conditions in the differential include Seckel syndrome, Cornelia de Lange syndrome, Rubinstein–Taybi syndrome, Wiedemann–Rautenstrauch syndrome, Rothmund–Thomson and Bloom syndromes, Hutchinson–Gilford progeria, Werner syndrome, primary mitochondrial disorders, congenital infections, and MORC2-related disorder, which can closely mimic Cockayne syndrome but is dominantly inherited and has normal DNA repair.¹

Research: is a cure coming?

No therapy has yet been proved to change the course of Cockayne syndrome, and none is available to patients.¹ Research is nonetheless moving, and gene therapy is the most advanced approach.

Why gene therapy is difficult in type B. Gene therapies usually deliver a working copy of a gene inside an adeno-associated virus (AAV). An AAV can carry only about 4.7–4.9 kilobases of genetic material — experiments show packaged genomes never exceed roughly 5.2 kb, and over-sized vectors are truncated and work poorly.¹⁷¹⁸ The coding sequence of ERCC6 alone is about 4.5 kb, which leaves almost no room for the control elements a vector also needs. The coding sequence of ERCC8, the gene behind type A, is only about 1.2 kb — small enough to fit inside an AAV comfortably, which is one reason type A programmes have advanced faster.²³

Progress so far:

• In 2026, researchers reported that an AAV9 vector carrying the human CSA gene, injected into the brains of newborn mice modelling Cockayne syndrome type A, significantly extended their lifespan. As far as we can tell, this is the first time a gene therapy has been shown to extend survival in a living animal model of Cockayne syndrome; the authors say it opens the door to a first human trial. Abnormalities in the brain did still persist.¹⁹
• A 126-base-pair “mini-promoter” designed specifically because ERCC6 is too large for a conventional promoter was published in 2026 by a group including researchers at the University of Minnesota. In the central nervous system it drove expression comparable to much larger standard promoters, with less activity in liver and kidney — a step towards a vector that can carry the CSB gene.¹⁸
• Work on the biology of type B continues, with recent reviews pointing to the combination of DNA damage, transcriptional dysregulation and mitochondrial dysfunction as the target.²⁰
• In Portugal, Dr Clévio Nóbrega’s group at the Algarve Biomedical Center Research Institute (ABC-RI) has run the CureCSB project to develop a gene therapy for Cockayne syndrome type B. In 2023 ABC-RI announced that he had received a €1 million project from our association, to build a platform for developing gene therapies for rare diseases.²²

Studies you can take part in. There is no treatment trial for Cockayne syndrome open anywhere in the world today — we would rather tell you that than let you discover it yourself. There are, however, natural history studies that are recruiting, and they matter: they are how researchers learn what the disease actually does over time, which is what any future trial will be measured against. The team at the University of Minnesota runs one for DNA repair disorders.²⁷ Ask your specialist about it, or search clinicaltrials.gov.

Other research directions. Gene therapy is not the only avenue. Work in mice published in 2025 showed kidney disease closely resembling the kidney problems seen in children with Cockayne syndrome, and traced it to a fault in how the kidney makes NAD⁺ — the first mechanistic account of a complication families already live with.²⁶ Other groups are testing whether medicines that already exist might help; that work is at the stage of cells in a dish and simple animal models, has not yet been reviewed by other scientists, and is no reason to give a child any supplement or medicine. Please do not act on it without your child’s doctor.

Families who would like to support this work can donate; families living with the condition are welcome to join our patient registry, which helps researchers plan studies and lets us reach you when something changes.

Support for families

Living with Cockayne syndrome is demanding, and no family should do it alone. Alongside our association, these organisations support families and research internationally:

• Cockayne Syndrome Foundation / National Initiative for Cockayne Syndrome (USA) — family and caregiver support, caregiver and clinician manuals, education and research.
• Share & Care Cockayne Syndrome and Trichothiodystrophy Network (USA) — founded in 1981; medical resources, financial assistance, a natural history study and an annual conference.
• Riaan Research Initiative (USA) — funds gene therapy, gene editing and drug repurposing research, with a current focus on type A, and runs a family registry.
• Amy and Friends (UK) — support, respite and bereavement care for families affected by childhood DNA repair disorders.

Ask about children’s palliative care early. It is not the same as giving up. For a progressive condition it usually means a second team whose whole job is comfort, symptom control, respite and supporting the family, running alongside everything else, sometimes for years. Ask too about what happens as your child grows up: families often find the move from children’s to adult services the hardest part, partly because adult services are not set up for young people of this size.¹⁰ And if the worst comes, you do not have to be alone with it — Amy and Friends supports families through anticipatory grief and bereavement.

If your child has just been diagnosed, ask your team for a referral to a clinical geneticist, and ask about the surveillance schedule above. And please write to us — we are parents too.

Frequently asked questions about Cockayne syndrome

References

1. Laugel V. Cockayne Syndrome. In: GeneReviews®. Seattle: University of Washington; 2000, updated 29 August 2024. https://www.ncbi.nlm.nih.gov/books/NBK1342/
2. MedlinePlus Genetics. Cockayne syndrome. US National Library of Medicine. https://medlineplus.gov/genetics/condition/cockayne-syndrome/
3. MedlinePlus Genetics. ERCC6 gene. US National Library of Medicine. https://medlineplus.gov/genetics/gene/ercc6/
4. Orphanet. Cockayne syndrome, ORPHA:191. https://www.orpha.net/en/disease/detail/191
5. National Organization for Rare Disorders (NORD). Cockayne Syndrome. https://rarediseases.org/rare-diseases/cockayne-syndrome/
6. Kleijer WJ, Laugel V, Berneburg M, et al. Incidence of DNA repair deficiency disorders in western Europe. DNA Repair (Amst). 2008;7(5):744–50. PMID 18329345. https://pubmed.ncbi.nlm.nih.gov/18329345/
7. Kubota M, Ohta S, Ando A, et al. Nationwide survey of Cockayne syndrome in Japan. Pediatr Int. 2015;57(3):339–47. PMID 25851792. https://pubmed.ncbi.nlm.nih.gov/25851792/
8. Natale V. A comprehensive description of the severity groups in Cockayne syndrome. Am J Med Genet A. 2011;155A(5):1081–95. PMID 21480477. https://pubmed.ncbi.nlm.nih.gov/21480477/
9. Nance MA, Berry SA. Cockayne syndrome: review of 140 cases. Am J Med Genet. 1992;42(1):68–84. PMID 1308368. https://pubmed.ncbi.nlm.nih.gov/1308368/
10. Wilson BT, Stark Z, Sutton RE, et al. The Cockayne Syndrome Natural History (CoSyNH) study: clinical findings in 102 individuals and recommendations for care. Genet Med. 2016;18(5):483–93. PMID 26204423. https://pmc.ncbi.nlm.nih.gov/articles/PMC4857186/
11. Wilson BT, Strong A, O'Kelly S, et al. Metronidazole toxicity in Cockayne syndrome: a case series. Pediatrics. 2015;136(3):e706–8. PMID 26304821. https://pubmed.ncbi.nlm.nih.gov/26304821/
12. Karikkineth AC, Scheibye-Knudsen M, Fivenson E, et al. Cockayne syndrome: clinical features, model systems and pathways. Ageing Res Rev. 2017;33:3–17. PMID 27507608. https://pubmed.ncbi.nlm.nih.gov/27507608/
13. Rajamani G, Stafki SA, Daugherty AL, et al. Cognitive decline and other late-stage neurologic complications in Cockayne syndrome. Neurol Clin Pract. 2024;14(4):e200309. PMID 38808024. https://pubmed.ncbi.nlm.nih.gov/38808024/
14. Kraemer KH, DiGiovanna JJ, Tamura D. Xeroderma Pigmentosum. In: GeneReviews®. Seattle: University of Washington; updated 24 March 2022. https://www.ncbi.nlm.nih.gov/books/NBK1397/
15. Natale V, Raquer H. Xeroderma pigmentosum-Cockayne syndrome complex. Orphanet J Rare Dis. 2017;12(1):65. PMID 28376890. https://pubmed.ncbi.nlm.nih.gov/28376890/
16. Baer S, Tuzin N, Kang PB, et al. Growth charts in Cockayne syndrome type 1 and type 2. Eur J Med Genet. 2021;64(1):104105. PMID 33227433. https://pubmed.ncbi.nlm.nih.gov/33227433/
17. Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther. 2010;18(1):80–6. PMID 19904234. https://pubmed.ncbi.nlm.nih.gov/19904234/
18. Chauhan M, Daugherty AL, Khadir F, et al. Design and initial characterization of a novel mini-promoter for gene therapies targeting the central nervous system. Mol Ther Adv. 2026;34(1):201681. PMID 42137269. https://pmc.ncbi.nlm.nih.gov/articles/PMC13148911/
19. Batista AR, Scholand AC, Callahan WS, et al. AAV-mediated gene therapy demonstrates phenotypic rescue in a mouse model of Cockayne syndrome. J Clin Invest. 2026 (online ahead of print). PMID 42531030. https://pubmed.ncbi.nlm.nih.gov/42531030/
20. Afonso-Reis R, Madeira CR, Brito DVC, Nóbrega C. Insights into Cockayne syndrome type B: what underlies its pathogenesis? Aging Cell. 2025;24(7):e70136. PMID 40536083. https://pubmed.ncbi.nlm.nih.gov/40536083/
21. Anandanadesan R, Tupprasoot R. Anaesthesia for children with DNA repair disorders. BJA Educ. 2025;25(9):343–7. PMID 40842920. https://pmc.ncbi.nlm.nih.gov/articles/PMC12365512/
22. ABC-RI. ABC-RI researcher receives 1 million euros to study rare diseases in children. 4 July 2023. https://abcri.pt/news/abc-ri-researcher-receives-1-million-euros-to-study-rare-diseases-in-children/
23. NCBI Reference Sequence NM_000124.4 (ERCC6, coding sequence 4,482 bp) and NM_000082.4 (ERCC8, coding sequence 1,191 bp). https://www.ncbi.nlm.nih.gov/nuccore/NM_000124.4
24. Rossmanith R, Wolf HM, Geier CB. Immune dysfunction in nucleotide excision repair disorders: an underrecognized clinical phenotype. Front Immunol. 2026;17:1865775. PMID 42490886. https://pubmed.ncbi.nlm.nih.gov/42490886/
25. Spoden AM, McGrattan KE, Kang PB. Swallowing and communication in Cockayne syndrome: clinical characteristics and management. Am J Med Genet A. 2026;200(7):1465–78. PMID 41730799. https://pubmed.ncbi.nlm.nih.gov/41730799/
26. Pekhale K, et al. Cockayne syndrome mice reflect human kidney disease and are defective in de novo NAD biosynthesis. Cell Death Differ. 2025;32(11):2126–45. PMID 40374849. https://pubmed.ncbi.nlm.nih.gov/40374849/
27. ClinicalTrials.gov. Natural History Study for DNA Repair Disorders (NCT05484570), University of Minnesota — recruiting as of September 2026. https://clinicaltrials.gov/study/NCT05484570